132 related articles for article (PubMed ID: 15205325)
1. BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3.
Gilmore PM; McCabe N; Quinn JE; Kennedy RD; Gorski JJ; Andrews HN; McWilliams S; Carty M; Mullan PB; Duprex WP; Liu ET; Johnston PG; Harkin DP
Cancer Res; 2004 Jun; 64(12):4148-54. PubMed ID: 15205325
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.
Wu W; Pew T; Zou M; Pang D; Conzen SD
J Biol Chem; 2005 Feb; 280(6):4117-24. PubMed ID: 15590693
[TBL] [Abstract][Full Text] [Related]
4. Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock.
Uhlik MT; Abell AN; Johnson NL; Sun W; Cuevas BD; Lobel-Rice KE; Horne EA; Dell'Acqua ML; Johnson GL
Nat Cell Biol; 2003 Dec; 5(12):1104-10. PubMed ID: 14634666
[TBL] [Abstract][Full Text] [Related]
5. PB1 domains of MEKK2 and MEKK3 interact with the MEK5 PB1 domain for activation of the ERK5 pathway.
Nakamura K; Johnson GL
J Biol Chem; 2003 Sep; 278(39):36989-92. PubMed ID: 12912994
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.
Chabalier C; Lamare C; Racca C; Privat M; Valette A; Larminat F
Cell Cycle; 2006 May; 5(9):1001-7. PubMed ID: 16639080
[TBL] [Abstract][Full Text] [Related]
7. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway.
Yu C; Wang S; Dent P; Grant S
Mol Pharmacol; 2001 Jul; 60(1):143-54. PubMed ID: 11408609
[TBL] [Abstract][Full Text] [Related]
8. MEK kinase 3 directly activates MKK6 and MKK7, specific activators of the p38 and c-Jun NH2-terminal kinases.
Deacon K; Blank JL
J Biol Chem; 1999 Jun; 274(23):16604-10. PubMed ID: 10347227
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 interacts with poly(A)-binding protein: implication of BRCA1 in translation regulation.
Dizin E; Gressier C; Magnard C; Ray H; Décimo D; Ohlmann T; Dalla Venezia N
J Biol Chem; 2006 Aug; 281(34):24236-46. PubMed ID: 16782705
[TBL] [Abstract][Full Text] [Related]
10. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
11. Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells.
Shiah SG; Chuang SE; Kuo ML
Mol Pharmacol; 2001 Feb; 59(2):254-62. PubMed ID: 11160861
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the mitogen-activated protein kinase kinase 4 (MKK4)/c-Jun NH2-terminal kinase 1 and MKK3/p38 pathways regulated by MEK kinases 2 and 3. MEK kinase 3 activates MKK3 but does not cause activation of p38 kinase in vivo.
Deacon K; Blank JL
J Biol Chem; 1997 May; 272(22):14489-96. PubMed ID: 9162092
[TBL] [Abstract][Full Text] [Related]
13. Delta MEKK3:ER* activation induces a p38 alpha/beta 2-dependent cell cycle arrest at the G2 checkpoint.
Garner AP; Weston CR; Todd DE; Balmanno K; Cook SJ
Oncogene; 2002 Nov; 21(53):8089-104. PubMed ID: 12444545
[TBL] [Abstract][Full Text] [Related]
14. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1.
Zhou C; Smith JL; Liu J
Oncogene; 2003 Apr; 22(16):2396-404. PubMed ID: 12717416
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.
Sunters A; Madureira PA; Pomeranz KM; Aubert M; Brosens JJ; Cook SJ; Burgering BM; Coombes RC; Lam EW
Cancer Res; 2006 Jan; 66(1):212-20. PubMed ID: 16397234
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery.
Okano J ; Rustgi AK
J Biol Chem; 2001 Jun; 276(22):19555-64. PubMed ID: 11278851
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
Promkan M; Liu G; Patmasiriwat P; Chakrabarty S
Int J Cancer; 2009 Dec; 125(12):2820-8. PubMed ID: 19551867
[TBL] [Abstract][Full Text] [Related]
18. BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.
Yan Y; Spieker RS; Kim M; Stoeger SM; Cowan KH
Oncogene; 2005 May; 24(20):3285-96. PubMed ID: 15735702
[TBL] [Abstract][Full Text] [Related]
19. MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway.
Sun W; Kesavan K; Schaefer BC; Garrington TP; Ware M; Johnson NL; Gelfand EW; Johnson GL
J Biol Chem; 2001 Feb; 276(7):5093-100. PubMed ID: 11073940
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells.
Stadheim TA; Xiao H; Eastman A
Cancer Res; 2001 Feb; 61(4):1533-40. PubMed ID: 11245462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
